Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 6:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 387 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Albuterol Clear all
Completed No phase listed Observational

Replication of the INSPIRE Trial in Healthcare Claims Data

NCT05179512
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Tiotropium, salmeterol-fluticasone
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
40 Years to 80 Years
Enrollment
98,278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 20, 2026, 6:15 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Diagnosis of Exercise-induced Bronchospasm (EIB) and Asthma in National Collegiate Athletic Association (NCAA) Division I Athletes

NCT00752167
View directory record Official record
Conditions
Exercise Induced Bronchospasm, Asthma
Interventions
Not listed
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated May 12, 2016 · Synced Oct 20, 2026, 6:15 AM EDT
Completed Phase 3 Interventional

Survival Of Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT00268216
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Salmeterol 50mcg/ Fluticasone Propionate 500mcg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 80 Years
Enrollment
6,228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
190
States / cities
Birmingham, Alabama • Jasper, Alabama • Mobile, Alabama + 152 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2017 · Synced Oct 20, 2026, 6:15 AM EDT
Terminated Phase 3 Interventional Results available

A Twelve Month Long Term Safety Study to Evaluate the Safety of Albuterol in a Dry Powder Inhaler With Both Repeated and as Needed Dosing

NCT01218009
View directory record Official record
Conditions
Asthma
Interventions
Placebo Spiromax, Albuterol Spiromax
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
30
States / cities
Scottsdale, Arizona • Los Angeles, California • San Diego, California + 27 more
Source: ClinicalTrials.gov public record
Updated May 20, 2015 · Synced Oct 20, 2026, 6:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Pharmacokinetic Bioequivalence of Budesonide and Albuterol With an Alternate Propellant Compared to Current Propellant.

NCT06139991
View directory record Official record
Conditions
Heathy Participants
Interventions
Treatment A (BDA MDI HFO), Treatment B (BDA MDI HFA)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 60 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 20, 2026, 6:15 AM EDT
Completed Not applicable Interventional Results available

COPD Assessment and Management Bundle Versus Usual Care

NCT01833026
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Spirometry test, Levalbuterol
Device · Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
40 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 24, 2019 · Synced Oct 20, 2026, 6:15 AM EDT
Completed Phase 2 Interventional Results available

An Evaluation of Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma

NCT01854047
View directory record Official record
Conditions
Asthma
Interventions
Dupilumab, placebo, ICS/LABA therapy, Salbutamol/albuterol, Levosalbutamol/levalbuterol
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
776 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
50
States / cities
Fullerton, California • Huntington Beach, California • Los Angeles, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2017 · Synced Oct 20, 2026, 6:15 AM EDT
Completed Phase 3 Interventional

Dose Response Study of Levalbuterol in the Prevention of Exercise Induced Bronchoconstriction Compared to Racemic Albuterol

NCT00685425
View directory record Official record
Conditions
Asthma, Bronchoconstriction
Interventions
Levalbuterol HFA MDI, Racemic Albuterol
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
12 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
5
States / cities
Los Angeles, California • Signal Hill, California • Denver, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2012 · Synced Oct 20, 2026, 6:15 AM EDT
Completed Phase 4 Interventional Results available

ED-Initiated School-based Asthma Medication Supervision

NCT03952286
View directory record Official record
Conditions
Asthma, Asthma in Children
Interventions
ED-Dispensing home and school supervision
Drug
Lead sponsor
University of Arizona
Other
Eligibility
6 Years to 12 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Oct 20, 2026, 6:15 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study of Drug Exposure in Systemic Circulation of Primatene Mist by Oral Inhalation, Versus Epinephrine Injection by Intramuscular Injection and ProAir by Oral Inhalation in Healthy Individuals

NCT04207840
View directory record Official record
Conditions
Pharmacokinetics, Epinephrine, Albuterol, Asthma, Anaphylaxis
Interventions
Epinephrine (0.125 mg/inhalation), Epinephrine Injection Auto-Injector (0.3mg/0.3mL), Albuterol Sulfate (0.09 mg/inhalation)
Combination Product
Lead sponsor
Amphastar Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Mar 30, 2021 · Synced Oct 20, 2026, 6:15 AM EDT
Completed Not applicable Interventional Results available

Response to Albuterol Delivered Through an Anti-static Valved Holding Chamber During Nocturnal Bronchospasm

NCT01111110
View directory record Official record
Conditions
Asthma
Interventions
anti-static then static, Static then anti-static chamber
Device
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 28, 2022 · Synced Oct 20, 2026, 6:15 AM EDT
Not listed Phase 3 Interventional

Bronchoprovocation Study to Evaluate the Pharmacodynamics of Albuterol Sulfate Inhalation Aerosol, eq 90 mcg Base

NCT03549897
View directory record Official record
Conditions
Asthma
Interventions
Placebo, 90 mcg Reference Product, 180 mcg Reference Product, 90 mcg Test Product
Drug
Lead sponsor
Amneal Ireland Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Brookhaven, New York
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Oct 20, 2026, 6:15 AM EDT
Completed Phase 3 Interventional Results available

Chronic-Dose Safety and Efficacy Study of Albuterol-HFA-BAI in Pediatric Asthmatics

NCT00308685
View directory record Official record
Conditions
Asthma
Interventions
Albuterol, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
4 Years to 11 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
14
States / cities
Little Rock, Arkansas • Huntington Beach, California • San Jose, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2022 · Synced Oct 20, 2026, 6:15 AM EDT
Completed Phase 4 Interventional Results available

Teva Asthma Predictive Analytics Study

NCT04997304
View directory record Official record
Conditions
Asthma
Interventions
AirDuo Digihaler, ProAir Digihaler
Combination Product
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 8, 2025 · Synced Oct 20, 2026, 6:15 AM EDT
Completed Phase 1 Interventional

Albuterol in Individuals With Late Onset Pompe Disease (LOPD)

NCT01859624
View directory record Official record
Conditions
Pompe Disease
Interventions
Albuterol
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 5, 2019 · Synced Oct 20, 2026, 6:15 AM EDT
Withdrawn Phase 2Phase 3 Interventional

Nebulized Albuterol for Congestive Heart Failure Exacerbation

NCT01375361
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
Albuterol, Normal Saline
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 10, 2013 · Synced Oct 20, 2026, 6:15 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Use of an Oral Beta-2 Agonist in Persons With Spinal Cord Injury

NCT00755079
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
extended release beta-2 adrenergic agonist, placebo
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Oct 20, 2026, 6:15 AM EDT
Completed No phase listed Observational

A Study to Evaluate the Integrated Dose Counter on an Albuterol Hydrofluoroalkane (HFA) Metered Dose Inhaler (MDI)

NCT01302587
View directory record Official record
Conditions
Asthma, Chronic Obstructive Pulmonary Disease (COPD), Emphysema, Chronic Bronchitis
Interventions
Albuterol
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
4 Years and older
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
25
States / cities
Glendale, Arizona • Mission Viejo, California • Orange, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2012 · Synced Oct 20, 2026, 6:15 AM EDT
Suspended Not applicable Interventional

A Multi-Centered Study of the Long-Term Effect of Salmeterol and Albuterol in Cystic Fibrosis

NCT00005110
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Salmeterol, Albuterol
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
5 Years to 45 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 20, 2026, 6:15 AM EDT
Completed Phase 3 Interventional

Long Term Safety Study of Levalbuterol and Racemic Albuterol in Subjects Twelve Years of Age and Older With Asthma

NCT00064389
View directory record Official record
Conditions
Asthma
Interventions
levalbuterol tartrate HFA MDI, racemic albuterol
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
12 Years and older
Enrollment
746 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
91
States / cities
Birmington, Alabama • Mobile, Alabama • Montgomery, Alabama + 79 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2012 · Synced Oct 20, 2026, 6:15 AM EDT
Terminated Phase 4 Interventional Results available

Inpatient Clinical Trial of NAC

NCT03581084
View directory record Official record
Conditions
Asthma
Interventions
N-acetylcysteine
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 80 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 26, 2021 · Synced Oct 20, 2026, 6:15 AM EDT
Terminated Phase 4 Interventional Results available

A Pilot Study to Determine the Most Effective Dose of Arformoterol for Treating Acute Asthmatic Patients

NCT00819637
View directory record Official record
Conditions
Acute Asthma
Interventions
arformoterol (RR formoterol), placebo, levalbuterol
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 45 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated May 24, 2023 · Synced Oct 20, 2026, 6:15 AM EDT
Completed Phase 2 Interventional

Safety and Tolerability Study of Levalbuterol HFA and Racemic Albuterol HFA in Pediatrics Subjects With Asthma

NCT00684866
View directory record Official record
Conditions
Asthma
Interventions
Levalbuterol HFA MDI followed by Racemic albuterol HFA MDI, Racemic Albuterol followed by levalbuterol HFA MDI
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
4 Years to 11 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
11
States / cities
Madera, California • San Diego, California • Savannah, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2012 · Synced Oct 20, 2026, 6:15 AM EDT
Completed Phase 3 Interventional Results available

Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) Exacerbations

NCT01120691
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
QVA149, NVA237, tiotropium, Salbutamol/albuterol
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
2,224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
53
States / cities
Birmingham, Alabama • Fairhope, Alabama • Florence, Alabama + 46 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2013 · Synced Oct 20, 2026, 6:15 AM EDT